In addition, we show that ixazomib is active against MYC/BCL2 DHL, MYC/BCL2 DEL cell lines, mutant p53 DLBCL cell lines, and doxorubicin-resistant DLBCL cell lines. Here, BCL2 is linked to diffuse large B-cell lymphoma.